Atomo Lack Capacity to Suppy

The big problem with this company is its inability to produce supply. Elume are producing 25m RAT's a month where AT1 is only 2m/month. This would prohibit there ability to get any serious government contracts. Given we are now 18 months into covid this is really poor management.
Australia will have at least 2.3-3bn requirement of RAT's.
Elume are selling their RAT's via pharmacies at $30/test. and have a contract with NIH for hundreds of millions. They were smart in outsourcing the product to Bosch.
AT1 needs to do the same as no gov is going to bother with a producer of 20m a year.